Press release
Investigation announced for Investors in shares of Travere Therapeutics, Inc. (NASDAQ: TVTX) over possible Violations of Securities Laws
An investigation for investors in Travere Therapeutics, Inc. (NASDAQ: TVTX) shares over potential securities laws violations.
Investors who purchased shares of Travere Therapeutics, Inc. (NASDAQ: TVTX), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm focuses on whether a series of statements by Travere Therapeutics, Inc. regarding its business, its prospects and its operations were materially false and misleading at the time they were made.
San Diego, CA based Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Travere Therapeutics, Inc. reported that its annual Total Revenue declined from $227.49 million in 2021 to $212.01 million in 2022, and that its Net Loss increased from $180.09 million in 2021 to $278.48 million in 2022.
Shares of Travere Therapeutics, Inc. (NASDAQ: TVTX) declined from $29.14 per share on August 08, 2022, to as low as $14.94 per share on July 17, 2023.
Those who purchased shares of Travere Therapeutics, Inc. (NASDAQ: TVTX) have certain options and should contact the Shareholders Foundation.
Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Investigation announced for Investors in shares of Travere Therapeutics, Inc. (NASDAQ: TVTX) over possible Violations of Securities Laws here
News-ID: 3152060 • Views: …
More Releases from Shareholders Foundation
ALERT: Lawsuit filed for Investors who SOLD shares of Sina Corporation (formerly …
An investor, who sold shares of Sina Corporation (formerly NASDAQ: SINA) in the merger between Seina Corporation and TuSimple Holdings, Inc, filed a lawsuit over alleged violations of Federal Securities Laws by Sina Corporation (formerly NASDAQ: SINA in connection with certain allegedly false and misleading statements made.
If you sold a significant amount of shares of Sina Corporation (formerly NASDAQ: SINA) between October 13, 2020 and March 22, 2021, you have…
Lawsuit Alert: Investors who lost money with shares of Fluor Corporation (NYSE: …
An investor, who purchased shares of Fluor Corporation (NYSE: FLR), filed a lawsuit alleged violations of Federal Securities Laws by Fluor Corporation in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Fluor Corporation (NYSE: FLR) have certain options and for certain investors are short and strict deadlines running. Deadline: November 14, 2025. NYSE: FLR investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779…
Investigation announced for Long-Term Investors in shares of Sable Offshore Corp …
An investigation was announced for long-term investors in shares of Sable Offshore Corp. (NYSE: SOC) concerning potential breaches of fiduciary duties by certain directors of Sable Offshore Corp.
Investors who are current long term investors in Sable Offshore Corp. (NYSE: SOC) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in…
Lawsuit filed for Investors who lost money with shares of Lantheus Holdings, Inc …
An investor, who purchased shares of Lantheus Holdings, Inc. (NASDAQ: LNTH), filed a lawsuit over alleged violations of Federal Securities Laws by Lantheus Holdings, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Lantheus Holdings, Inc. (NASDAQ: LNTH) have certain options and for certain investors are short and strict deadlines running. Deadline: November 10, 2025. NASDAQ: LNTH investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com…
More Releases for Travere
Rare Kidney Diseases Treatment Market Is Booming Worldwide with Biotech Drug Adv …
Rare Kidney Diseases Treatment Market Snapshot
The Rare Kidney Diseases Treatment Market is projected to reach USD 9.07 billion by 2032, growing at a CAGR of 11.4% from 2025 to 2032.
Coherent Market Insights proudly presents its latest Rare Kidney Diseases Treatment Market Research Report, delivering a detailed examination of the U.S. Rare Kidney Diseases Treatment Market outlook from 2025 to 2032. This comprehensive analysis provides strategic forecasts at both national and…
Homocystinuria Market Growth, Trends & Forecast 2025 | Leading key players - Tra …
The Global Homocystinuria Market is expected to reach at a Significant CAGR during the forecast period 2024-2031.
Homocystinuria Market report, published by DataM Intelligence, delivers detailed insights and analysis on major market trends, growth prospects, and emerging challenges. With a strong focus on providing actionable intelligence, DataM Intelligence enables businesses to make well-informed decisions and maintain a competitive edge. By blending both qualitative and quantitative research approaches, the company offers thorough…
Homocystinuria Market: Projected Positive Growth Trends through 2024-2031 - Trav …
The Homocystinuria Market study by DataM Intelligence offer an in-depth analysis of the market, presenting insightful observations, statistics, historical data, and industry-validated market insights. The report delves into the competitive positioning of key companies, examining factors such as product offerings, pricing strategies, financial health, product portfolios, growth initiatives, and geographical reach.
Download a Free sample PDF (Use Corporate email ID to Get Higher Priority) at: - https://datamintelligence.com/download-sample/homocystinuria-market
What is the projected growth…
ANCA Vasculitis Market to Rise by 2032 | AstraZeneca, GlaxoSmithKline, Travere T …
DelveInsight's "ANCA Vasculitis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of ANCA Vasculitis, historical and forecasted epidemiology as well as the ANCA Vasculitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The ANCA Vasculitis market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted ANCA Vasculitis market size…
Proteinuria Treatment Market - A Comprehensive Study by Key Players: Sanofi, Tra …
MR Forecast published a new research publication on "Proteinuria Treatment Market Insights, to 2032" with 232+ pages and enriched with self-explained Tables and charts in presentable format. In the Study you will find new evolving Trends, Drivers, Restraints, Opportunities generated by targeting market associated stakeholders. The growth of the Proteinuria Treatment market was mainly driven by the increasing R&D spending across the world.
Some of the key players profiled in the…
Travere Therapeutics "Sparsentan" Market size expansion of Several Folds by 2032
[Las Vegas, United States] DelveInsight, a leader in healthcare research firm, has recently published an in-depth report on Sparsentan (Travere Therapeutics) providing insights into the drug market landscape and market forecast of Sparsentan upto 2032. The report, titled "Sparsentan Market Size, Forecast, and Emerging Insight - 2032" is now available for review and analysis.
Are you interested in finding out the projected market size of Sparsentan in 2032? Sparsentan Market…
